Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 2018; 268: 215-222.

Published: 15th October 2018

Authors: Jang J-Y, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H et al.

Conclusion

Fifty patients were included. Neoadjuvant chemotherapy significantly improved median two year survival: 40.7 versus 26.1 per cent, P=0.028. It also improved the R0 resection rate: 51.8 versus 26.1 per cent, P=0.004.

Pubmed Link

Your comments

0 Comments